SlideShare a Scribd company logo
1 of 3
Download to read offline
Big Pharma's secret payments to corrupt doctors, scientists 
finally to be exposed by US government 
(NaturalNews) The legacy of back room wheelin' and dealin' by the drug industry, which routinely 
pays off doctors and academic researchers to hawk oftentimes dangerous and ineffective 
pharmaceuticals and medical devices, could soon be blown wide open by newly enacted legislation 
passed as part of the Affordable Care Act of 2010. 
The Physician Payments Sunshine Act, which was successfully moved through the Senate with the 
help of an extensive investigation led by Senator Charles Grassley (R-IA), provisions that doctors 
who receive payoffs from drug or vaccine companies must disclose this when pushing new therapies 
or medical procedures from what would otherwise appear to be unbiased intentions. 
The law was reportedly added to Obamacare because it was unlikely to pass on its own due to 
intense industry pressures against any sort of reform. Paying off doctors has become the bread and 
butter of Big Pharma drug marketing. It's both discreet and highly effective, repeatedly creating the 
illusion that the medical profession at large endorses the latest drugs and medical procedures, many 
of which aren't safe and don't work. 
Many medical groups have become dependent upon drug industry payoffs 
According to the Harvard Business Review's (HBR) Paul Thacker, who served as Sen. Grassley's lead 
investigator from 2007 to 2010, doctors and medical groups routinely accepts cash payments from 
the drug industry for speaking engagements, scientific papers, and other medical propaganda 
designed to make drugs and medical devices appear safer and more effective than they actually are. 
An investigation spearheaded by NPR (National Public Radio), Consumer Reports, and ProPublica 
found that in the three years leading up to its publishing in late 2010, drug companies had settled 
cases totaling $7 billion for paying doctors to promote drugs. In many cases, doctors were 
encouraged to prescribe drugs for off-label conditions, or to prescribe expensive drugs when they 
weren't actually needed. 
"Companies were paying physicians to give speeches on behalf of their products and to publish 
studies (ghostwritten by the companies) that downplayed those products' side effects," wrote 
Thacker in a recent piece for HBR, noting that many medical professionals have been resistant to 
congressional efforts to reign in this unconscionably deceitful practice. 
"After we launched investigations of more than three dozen patient-advocacy groups and 
professional medical societies, it became clear why: Most of those organizations depended on 
income from industry, and many physician-leaders of these groups received large consulting fees." 
Disclosure doesn't always deter drug industry corruption 
Though drug companies have had to fork out billions of dollars' worth of fines in recent years for 
defrauding the government and pushing many a dangerous and ineffective drug on consumers, 
including the infamous Vioxx and Avandia scandals, it is still apparently worth it for the industry to 
use trusted physicians as mouthpieces for ruthless drug promotion. 
And even with tighter restrictions on payment disclosure, drug companies are likely to continue
bribing the medical industry to push their unsafe and potentially deadly products. According to a 
2012 study published in the journal JAMA Internal Medicine, formerly known as Archives of Internal 
Medicine, disclosure requirements are unlikely to affect either prescribing behavior or health care 
costs, which could render them moot. 
At the same time, a separate study 
published in the New England Journal of 
Medicine (NEJM) revealed that disclosure 
does affect the way some physicians view 
published medical studies. When it is 
transparent that a paper was funded or 
ghostwritten by a drug company, doctors 
are likely to scrutinize it more harshly, 
found researchers. 
Science journals even more plagued by 
conflicts of interest 
Interestingly, medical science has made much greater strides towards addressing conflicts of 
interest problems than general science. While NEJM and JAMA instituted their first conflict of 
interest policies back in 1984 and 1985, respectively, the two leading science journals, Science and 
Nature, didn't institute theirs until 1992 and 2001, respectively. 
In 2009, researchers from Tufts University found that science journals have almost always lagged 
behind medical journals in addressing conflicts of interest, and are generally worse at enforcing 
their already established disclosure policies. 
"Industry has funded campaigns to undermine scientific work that has major public health 
implications, such as secondhand smoking, obesity, regulation of chemicals, and climate change," 
added Thacker. "In each case, hidden money buys off science experts, funds think-tank papers, and 
litters journals with ghostwritten studies." 
Thacker's solutions include requiring all agencies that deal with the publishing of science to fully 
disclose all income sources and other potential conflicts of interest. He also urges the medical 
community to adopt universal reporting standards that others in the field of science can mimic, 
while at the same time disallowing the further publishing of any ghostwritten studies drafted by 
special interests. 
Sources: 
http://www.gpo.gov (pdf) 
http://www.naturalnews.com 
http://archinte.jamanetwork.com 
http://www.nejm.org
http://www.tandfonline.com 
Please enable JavaScript to view the comments powered by Disqus. 
comments powered by 
Take Action: Support NaturalNews.com by linking back to this article from your website 
Permalink to this article: 
http://www.naturalnews.com/047941_Sunshine_law_corruption_pharmaceuticals.html 
Embed article link: (copy HTML code below): 
Big Pharma's secret payments to corrupt doctors, scientists finally to be exposed by US government 
Reprinting this article: 
Non-commercial use OK, cite NaturalNews.com with clickable link. 
Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest 
http://www.naturalnews.com/047941_Sunshine_law_corruption_pharmaceuticals.html

More Related Content

What's hot

Literature searches in Pharmacovigilance
Literature searches in PharmacovigilanceLiterature searches in Pharmacovigilance
Literature searches in Pharmacovigilancesamikshagupta
 
Nys release of drugstoreboycott
Nys release of drugstoreboycottNys release of drugstoreboycott
Nys release of drugstoreboycottblumarchive
 
PSM Interchange 2014 Panel 3: Daniel Burke: The Impacts of Fake Online Pharma...
PSM Interchange 2014 Panel 3: Daniel Burke: The Impacts of Fake Online Pharma...PSM Interchange 2014 Panel 3: Daniel Burke: The Impacts of Fake Online Pharma...
PSM Interchange 2014 Panel 3: Daniel Burke: The Impacts of Fake Online Pharma...The Partnership For Safe Medicines
 
Medical Device Librarianship 101 V11 Prepub
Medical Device Librarianship 101 V11 PrepubMedical Device Librarianship 101 V11 Prepub
Medical Device Librarianship 101 V11 Prepubahgong86
 
Avoidable Patient Harm and Resulting Liability
Avoidable Patient Harm and Resulting Liability Avoidable Patient Harm and Resulting Liability
Avoidable Patient Harm and Resulting Liability Arete-Zoe, LLC
 
Hit-Miss Model for Duplicate Detection-WHO Drug Safety Database_PVER Conf_May...
Hit-Miss Model for Duplicate Detection-WHO Drug Safety Database_PVER Conf_May...Hit-Miss Model for Duplicate Detection-WHO Drug Safety Database_PVER Conf_May...
Hit-Miss Model for Duplicate Detection-WHO Drug Safety Database_PVER Conf_May...NORC at the University of Chicago
 
The Economics of Quality in Healthcare
The Economics of Quality in HealthcareThe Economics of Quality in Healthcare
The Economics of Quality in HealthcareSage Growth Partners
 
Cell centered database for immunology and cancer research feb252016
Cell centered database for immunology and cancer research feb252016Cell centered database for immunology and cancer research feb252016
Cell centered database for immunology and cancer research feb252016Ann-Marie Roche
 
Corruption Risks in the Healthcare Marketplace: Why Transparency is the Righ...
Corruption Risks in the Healthcare Marketplace:  Why Transparency is the Righ...Corruption Risks in the Healthcare Marketplace:  Why Transparency is the Righ...
Corruption Risks in the Healthcare Marketplace: Why Transparency is the Righ...MeTApresents
 
Drug analytics based on triple linking v1.0
Drug analytics based on triple linking v1.0Drug analytics based on triple linking v1.0
Drug analytics based on triple linking v1.0Ann-Marie Roche
 
Biomarkers brain regions
Biomarkers brain regionsBiomarkers brain regions
Biomarkers brain regionsAnn-Marie Roche
 
Guidelines to authors in Writing an effective Medical Case Report - Scientifi...
Guidelines to authors in Writing an effective Medical Case Report - Scientifi...Guidelines to authors in Writing an effective Medical Case Report - Scientifi...
Guidelines to authors in Writing an effective Medical Case Report - Scientifi...Pubrica
 

What's hot (20)

Literature searches in Pharmacovigilance
Literature searches in PharmacovigilanceLiterature searches in Pharmacovigilance
Literature searches in Pharmacovigilance
 
Nys release of drugstoreboycott
Nys release of drugstoreboycottNys release of drugstoreboycott
Nys release of drugstoreboycott
 
PSM Interchange 2014 Panel 3: Daniel Burke: The Impacts of Fake Online Pharma...
PSM Interchange 2014 Panel 3: Daniel Burke: The Impacts of Fake Online Pharma...PSM Interchange 2014 Panel 3: Daniel Burke: The Impacts of Fake Online Pharma...
PSM Interchange 2014 Panel 3: Daniel Burke: The Impacts of Fake Online Pharma...
 
Medical Device Librarianship 101 V11 Prepub
Medical Device Librarianship 101 V11 PrepubMedical Device Librarianship 101 V11 Prepub
Medical Device Librarianship 101 V11 Prepub
 
Avoidable Patient Harm and Resulting Liability
Avoidable Patient Harm and Resulting Liability Avoidable Patient Harm and Resulting Liability
Avoidable Patient Harm and Resulting Liability
 
Chantix Writing Sample
Chantix Writing SampleChantix Writing Sample
Chantix Writing Sample
 
Panel: Open Access- Peter Doshi
Panel: Open Access- Peter DoshiPanel: Open Access- Peter Doshi
Panel: Open Access- Peter Doshi
 
Hit-Miss Model for Duplicate Detection-WHO Drug Safety Database_PVER Conf_May...
Hit-Miss Model for Duplicate Detection-WHO Drug Safety Database_PVER Conf_May...Hit-Miss Model for Duplicate Detection-WHO Drug Safety Database_PVER Conf_May...
Hit-Miss Model for Duplicate Detection-WHO Drug Safety Database_PVER Conf_May...
 
The Single-Payer Tornado
The Single-Payer TornadoThe Single-Payer Tornado
The Single-Payer Tornado
 
The Economics of Quality in Healthcare
The Economics of Quality in HealthcareThe Economics of Quality in Healthcare
The Economics of Quality in Healthcare
 
Cell centered database for immunology and cancer research feb252016
Cell centered database for immunology and cancer research feb252016Cell centered database for immunology and cancer research feb252016
Cell centered database for immunology and cancer research feb252016
 
Corruption Risks in the Healthcare Marketplace: Why Transparency is the Righ...
Corruption Risks in the Healthcare Marketplace:  Why Transparency is the Righ...Corruption Risks in the Healthcare Marketplace:  Why Transparency is the Righ...
Corruption Risks in the Healthcare Marketplace: Why Transparency is the Righ...
 
Drug analytics based on triple linking v1.0
Drug analytics based on triple linking v1.0Drug analytics based on triple linking v1.0
Drug analytics based on triple linking v1.0
 
Biomarkers brain regions
Biomarkers brain regionsBiomarkers brain regions
Biomarkers brain regions
 
NETWORK OF DISEASES AND ITS ENDOWMENT TOWARDS DISEASE
NETWORK OF DISEASES AND ITS ENDOWMENT TOWARDS DISEASE NETWORK OF DISEASES AND ITS ENDOWMENT TOWARDS DISEASE
NETWORK OF DISEASES AND ITS ENDOWMENT TOWARDS DISEASE
 
Emergency med pharmacist 2017 coralic a. et al
Emergency med pharmacist 2017 coralic a. et alEmergency med pharmacist 2017 coralic a. et al
Emergency med pharmacist 2017 coralic a. et al
 
chemotherapy radiology
 chemotherapy   radiology chemotherapy   radiology
chemotherapy radiology
 
Cdc concerns
Cdc concernsCdc concerns
Cdc concerns
 
American Journal of Emergency & Critical Care Medicine
American Journal of Emergency & Critical Care MedicineAmerican Journal of Emergency & Critical Care Medicine
American Journal of Emergency & Critical Care Medicine
 
Guidelines to authors in Writing an effective Medical Case Report - Scientifi...
Guidelines to authors in Writing an effective Medical Case Report - Scientifi...Guidelines to authors in Writing an effective Medical Case Report - Scientifi...
Guidelines to authors in Writing an effective Medical Case Report - Scientifi...
 

Similar to Big Pharma's secret payments to corrupt doctors, scientists finally to be exposed by US government

Collision Forces: Scientific Integrity Meets the Capital Markets
Collision Forces: Scientific Integrity Meets the Capital MarketsCollision Forces: Scientific Integrity Meets the Capital Markets
Collision Forces: Scientific Integrity Meets the Capital MarketsLindsay Meyer
 
Murky_Waters_of_Medical_Practice_in_India
Murky_Waters_of_Medical_Practice_in_IndiaMurky_Waters_of_Medical_Practice_in_India
Murky_Waters_of_Medical_Practice_in_IndiaSteven Cosgrove, Ph.D.
 
Conflict of interest week 3 written assignment mha
Conflict of interest week 3 written assignment mhaConflict of interest week 3 written assignment mha
Conflict of interest week 3 written assignment mhashendrix489
 
Dollars for doctors
Dollars for doctorsDollars for doctors
Dollars for doctorsbryan rahija
 
13. 2015 mwan 010815 testimony to federal election commission 1 8-15
13.  2015 mwan 010815  testimony to federal election commission  1 8-1513.  2015 mwan 010815  testimony to federal election commission  1 8-15
13. 2015 mwan 010815 testimony to federal election commission 1 8-15MedicalWhistleblower
 
Changing the Medical Research Paradigm
Changing the Medical Research ParadigmChanging the Medical Research Paradigm
Changing the Medical Research ParadigmRAWE_INC
 
Science As A Business
Science As A BusinessScience As A Business
Science As A BusinessChris Waller
 
Five Questions” You will write responses to five (5.docx
Five Questions” You will write responses to five (5.docxFive Questions” You will write responses to five (5.docx
Five Questions” You will write responses to five (5.docxRAJU852744
 
Ethics in pharma industry
Ethics in pharma industryEthics in pharma industry
Ethics in pharma industryDr Qureshi
 
Ethics from a Pharmaceutical Industry Perspective
Ethics from a Pharmaceutical Industry PerspectiveEthics from a Pharmaceutical Industry Perspective
Ethics from a Pharmaceutical Industry PerspectiveAlayjoshi0071
 
Top Trends in Orphan Drugs
Top Trends in Orphan DrugsTop Trends in Orphan Drugs
Top Trends in Orphan DrugsBill Smith
 
Medicalization, Markets and ConsumersAuthor(s) Peter .docx
  Medicalization, Markets and ConsumersAuthor(s) Peter .docx  Medicalization, Markets and ConsumersAuthor(s) Peter .docx
Medicalization, Markets and ConsumersAuthor(s) Peter .docxaryan532920
 
washingtonpost.com  Health
washingtonpost.com  Healthwashingtonpost.com  Health
washingtonpost.com  Healthtidwellerin392
 
Accountability in Healthcare: Collaboration and Analytics are Key
Accountability in Healthcare: Collaboration and Analytics are KeyAccountability in Healthcare: Collaboration and Analytics are Key
Accountability in Healthcare: Collaboration and Analytics are KeyBukmarker
 
GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...
GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...
GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...Nejmeddine Jemaa
 

Similar to Big Pharma's secret payments to corrupt doctors, scientists finally to be exposed by US government (20)

Collision Forces: Scientific Integrity Meets the Capital Markets
Collision Forces: Scientific Integrity Meets the Capital MarketsCollision Forces: Scientific Integrity Meets the Capital Markets
Collision Forces: Scientific Integrity Meets the Capital Markets
 
Murky_Waters_of_Medical_Practice_in_India
Murky_Waters_of_Medical_Practice_in_IndiaMurky_Waters_of_Medical_Practice_in_India
Murky_Waters_of_Medical_Practice_in_India
 
Conflict of interest week 3 written assignment mha
Conflict of interest week 3 written assignment mhaConflict of interest week 3 written assignment mha
Conflict of interest week 3 written assignment mha
 
The Power and Limitations of Markets in Addressing Medical Needs
The Power and Limitations of Markets in Addressing Medical NeedsThe Power and Limitations of Markets in Addressing Medical Needs
The Power and Limitations of Markets in Addressing Medical Needs
 
Dollars for doctors
Dollars for doctorsDollars for doctors
Dollars for doctors
 
13. 2015 mwan 010815 testimony to federal election commission 1 8-15
13.  2015 mwan 010815  testimony to federal election commission  1 8-1513.  2015 mwan 010815  testimony to federal election commission  1 8-15
13. 2015 mwan 010815 testimony to federal election commission 1 8-15
 
Ethics in Healthcare
Ethics in HealthcareEthics in Healthcare
Ethics in Healthcare
 
Changing the Medical Research Paradigm
Changing the Medical Research ParadigmChanging the Medical Research Paradigm
Changing the Medical Research Paradigm
 
Science As A Business
Science As A BusinessScience As A Business
Science As A Business
 
Ethical Behaviour
Ethical BehaviourEthical Behaviour
Ethical Behaviour
 
Five Questions” You will write responses to five (5.docx
Five Questions” You will write responses to five (5.docxFive Questions” You will write responses to five (5.docx
Five Questions” You will write responses to five (5.docx
 
Ethics in pharma industry
Ethics in pharma industryEthics in pharma industry
Ethics in pharma industry
 
Ethics from a Pharmaceutical Industry Perspective
Ethics from a Pharmaceutical Industry PerspectiveEthics from a Pharmaceutical Industry Perspective
Ethics from a Pharmaceutical Industry Perspective
 
Top Trends in Orphan Drugs
Top Trends in Orphan DrugsTop Trends in Orphan Drugs
Top Trends in Orphan Drugs
 
Medicalization, Markets and ConsumersAuthor(s) Peter .docx
  Medicalization, Markets and ConsumersAuthor(s) Peter .docx  Medicalization, Markets and ConsumersAuthor(s) Peter .docx
Medicalization, Markets and ConsumersAuthor(s) Peter .docx
 
Inside the FDA
Inside the FDAInside the FDA
Inside the FDA
 
washingtonpost.com  Health
washingtonpost.com  Healthwashingtonpost.com  Health
washingtonpost.com  Health
 
Accountability in Healthcare: Collaboration and Analytics are Key
Accountability in Healthcare: Collaboration and Analytics are KeyAccountability in Healthcare: Collaboration and Analytics are Key
Accountability in Healthcare: Collaboration and Analytics are Key
 
Dearth of funding transparency among patient advocacy groups
Dearth of funding transparency among patient advocacy groupsDearth of funding transparency among patient advocacy groups
Dearth of funding transparency among patient advocacy groups
 
GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...
GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...
GSK’S Andrew Witty: Addressing Neglected Tropical Diseases and global health ...
 

Big Pharma's secret payments to corrupt doctors, scientists finally to be exposed by US government

  • 1. Big Pharma's secret payments to corrupt doctors, scientists finally to be exposed by US government (NaturalNews) The legacy of back room wheelin' and dealin' by the drug industry, which routinely pays off doctors and academic researchers to hawk oftentimes dangerous and ineffective pharmaceuticals and medical devices, could soon be blown wide open by newly enacted legislation passed as part of the Affordable Care Act of 2010. The Physician Payments Sunshine Act, which was successfully moved through the Senate with the help of an extensive investigation led by Senator Charles Grassley (R-IA), provisions that doctors who receive payoffs from drug or vaccine companies must disclose this when pushing new therapies or medical procedures from what would otherwise appear to be unbiased intentions. The law was reportedly added to Obamacare because it was unlikely to pass on its own due to intense industry pressures against any sort of reform. Paying off doctors has become the bread and butter of Big Pharma drug marketing. It's both discreet and highly effective, repeatedly creating the illusion that the medical profession at large endorses the latest drugs and medical procedures, many of which aren't safe and don't work. Many medical groups have become dependent upon drug industry payoffs According to the Harvard Business Review's (HBR) Paul Thacker, who served as Sen. Grassley's lead investigator from 2007 to 2010, doctors and medical groups routinely accepts cash payments from the drug industry for speaking engagements, scientific papers, and other medical propaganda designed to make drugs and medical devices appear safer and more effective than they actually are. An investigation spearheaded by NPR (National Public Radio), Consumer Reports, and ProPublica found that in the three years leading up to its publishing in late 2010, drug companies had settled cases totaling $7 billion for paying doctors to promote drugs. In many cases, doctors were encouraged to prescribe drugs for off-label conditions, or to prescribe expensive drugs when they weren't actually needed. "Companies were paying physicians to give speeches on behalf of their products and to publish studies (ghostwritten by the companies) that downplayed those products' side effects," wrote Thacker in a recent piece for HBR, noting that many medical professionals have been resistant to congressional efforts to reign in this unconscionably deceitful practice. "After we launched investigations of more than three dozen patient-advocacy groups and professional medical societies, it became clear why: Most of those organizations depended on income from industry, and many physician-leaders of these groups received large consulting fees." Disclosure doesn't always deter drug industry corruption Though drug companies have had to fork out billions of dollars' worth of fines in recent years for defrauding the government and pushing many a dangerous and ineffective drug on consumers, including the infamous Vioxx and Avandia scandals, it is still apparently worth it for the industry to use trusted physicians as mouthpieces for ruthless drug promotion. And even with tighter restrictions on payment disclosure, drug companies are likely to continue
  • 2. bribing the medical industry to push their unsafe and potentially deadly products. According to a 2012 study published in the journal JAMA Internal Medicine, formerly known as Archives of Internal Medicine, disclosure requirements are unlikely to affect either prescribing behavior or health care costs, which could render them moot. At the same time, a separate study published in the New England Journal of Medicine (NEJM) revealed that disclosure does affect the way some physicians view published medical studies. When it is transparent that a paper was funded or ghostwritten by a drug company, doctors are likely to scrutinize it more harshly, found researchers. Science journals even more plagued by conflicts of interest Interestingly, medical science has made much greater strides towards addressing conflicts of interest problems than general science. While NEJM and JAMA instituted their first conflict of interest policies back in 1984 and 1985, respectively, the two leading science journals, Science and Nature, didn't institute theirs until 1992 and 2001, respectively. In 2009, researchers from Tufts University found that science journals have almost always lagged behind medical journals in addressing conflicts of interest, and are generally worse at enforcing their already established disclosure policies. "Industry has funded campaigns to undermine scientific work that has major public health implications, such as secondhand smoking, obesity, regulation of chemicals, and climate change," added Thacker. "In each case, hidden money buys off science experts, funds think-tank papers, and litters journals with ghostwritten studies." Thacker's solutions include requiring all agencies that deal with the publishing of science to fully disclose all income sources and other potential conflicts of interest. He also urges the medical community to adopt universal reporting standards that others in the field of science can mimic, while at the same time disallowing the further publishing of any ghostwritten studies drafted by special interests. Sources: http://www.gpo.gov (pdf) http://www.naturalnews.com http://archinte.jamanetwork.com http://www.nejm.org
  • 3. http://www.tandfonline.com Please enable JavaScript to view the comments powered by Disqus. comments powered by Take Action: Support NaturalNews.com by linking back to this article from your website Permalink to this article: http://www.naturalnews.com/047941_Sunshine_law_corruption_pharmaceuticals.html Embed article link: (copy HTML code below): Big Pharma's secret payments to corrupt doctors, scientists finally to be exposed by US government Reprinting this article: Non-commercial use OK, cite NaturalNews.com with clickable link. Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest http://www.naturalnews.com/047941_Sunshine_law_corruption_pharmaceuticals.html